Research & Publications
From sham to solution: Blood pressure drops after uRDN crossover
June 26, 2025
A new analysis from the RADIANCE clinical trial program1 reveals that patients with uncontrolled hypertension who crossed over to receive ultrasound renal denervation (uRDN) experienced significant and sustained reductions in blood pressure—without an increase in medication burden.
The study, led by Bloch and colleagues, pooled data from three international, randomized, sham-controlled trials (RADIANCE-HTN SOLO, TRIO, and RADIANCE II). It focused on 92 patients who initially received a sham procedure but later crossed over to receive uRDN due to uncontrolled blood pressure despite antihypertensive medications.
Key findings include:
- A mean reduction of 9.2 mmHg in daytime ambulatory systolic blood pressure (dASBP) at 12 months post-crossover.
- Office systolic BP dropped by an average of 5.6 mmHg, with no significant increase in the number of medications used.
- Nearly 40–45% of patients achieved daytime BP control (<135/85 mmHg) at follow-up visits.
- The procedure was well-tolerated, with no device- or procedure-related complications.
These results reinforce the clinical value of uRDN as a viable option for patients with persistent hypertension, especially in real-world settings where medication regimens are not strictly controlled. The findings also underscore the potential of uRDN to reduce cardiovascular risk, as even modest BP reductions are associated with significant decreases in major cardiovascular events.
While the study is observational and has limitations—including non-standardized medication use and incomplete 12-month follow-up for all patients—it adds important real-world evidence to the growing body of support for uRDN.
“These results show that ultrasound renal denervation can deliver meaningful and sustained blood pressure reductions even in real-world settings—without increasing medication burden. It’s a powerful validation of the therapy’s potential and a promising step toward broader adoption in the management of hypertension.” – Dr. Michael J. Bloch
Read the full study in Euro Intervention
Article: Changes in blood pressure after crossover to ultrasound renal denervation
References:
| 1 | Changes in blood pressure after crossover to ultrasound renal denervation; Michael J. Bloch et al; on behalf of the RADIANCE investigators; EuroIntervention 2025; 21:93-95; DOI: 10.4244/EIJ-D-24-00321 |
March 11, 2025
13 randomized sham-controlled trials (N=2,285) evaluated the efficacy and safety of ultrasound renal denervation (uRDN) and radiofrequency renal denervation (rRDN). uRDN demonstrated a greater reduction in ambulatory SBP across all time points.
